| [1] Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-386.[2] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.[3] Le Chevalier T,Scagliotti G,Natale R,et al.Efficacy ofgemcitabine plus platinum chemotherapy compared with otherplatinum containing regimens in advanced non-small-cell lung cancer:ameta-analysis of survival outcomes[J].Lung Cancer,2005,47(1):69-80.[4] Azzoli CG,Baker S Jr,Temin S,et al.American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer[J].J Clin Oncol,2010,13(3):171-189.[5] Schiller JH,Harrington D,Belani CP,et a1.Comparisonof four chemotherapy regimens for advanced non-small cell lung cancer[J].N Engl J Med,2002,346(2):92-98.[6] Taylor JG,Choi EH,Foster CB,et al.Using genetic variation to study humandisease[J].Trends Mol Med,2001,7(11):507-512.[7] Sugiyama E,Kaniwa N,Kim SR,et al.Pharmacokinetics of gemcitabinein Japanese cancer patients:the impact of a cytidine deaminase polymorphism[J].J Clin Oncol,2007,25(1):32-42.[8] Tibaldi C,Giovannetti,Vasile E,et al.Correlation of CDA,ERCC1,and XPD polymorphisms with response and survivalin gemcitabine/cisplatin treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2008,14(6):1797-1803[9] Eisenhauer EA,Therasse P,Bogaerts,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.[10] Marsh S,Mallon MA,Goodfellow P,et al.Concordance of pharmacogenetic markers in germline and colorectal tumor DNA[J].Pharmacogenomics,2005,6(8):873-877.[11] Teng YS,Anderson JE,Giblett ER. Cytidine deaminase:a new genetic polymorphism demonstrated in human granulocytes[J].Am J Hum Genet,1975,27(4):492-497.[12] Kühn K,Bertling WM,Emmrich F.Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation[J].Biochem Biophys Res Commun,1993,190(1):1-7.[13] Laliberté J,Momparler RL.Human cytidine deaminase:purification of enzyme,cloning,and expression of its complementary DNA[J].Cancer Res,1994,54(20):5401-5407.[14] Gilbert JA,Salavaggione OE,Ji Y,et al.Gemcita-bine pharmacogenomics:cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics[J].Clin Cancer Res,2006,12(6):1794-1803.[15] Vincenzetti S,Mariani PL,Cammertoni N,et al.Isoenzymatic forms of human cytidine deaminase[J].Protein Eng Des Sel,2004,17(12):871-877.[16] Xu J,Zhou Y,Zhang J,et al.High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation[J].Clin Chim Acta,2012,413(15/16):1284-1287.[17] Zhou M,Ding YJ,Feng Y,et al.Association of xeroderma pigmentosum group D(Asp312Asn,Lys751Gln) and cytidine deaminase (Lys27Gln,Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine[J].Genet Mol Res,2014,13(2):3310-3318.[18] Kirch HC,SchroderJ,Hoppe H,et al.Recombinant gene products of two natural variants of the humancytidine deaminase gene conferdifferent deamination rates of cytarabine in vitro[J].Exp Hematol,1998,26(5):421-425.[19] Maring JG, Wachters FM,Slijfer M,et al.Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients:impact of the 79A>C cytidine deaminase polymorphism[J].Eur J Clin Pharmacol,2010,66(6):611-617. |
